The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2004-04-28
Target enrollment:
Participant gender:
Summary
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary
albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2)
Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that
may be associated with it.